CRISIL reaffirms credit rating on Advanced Enzyme Technologies

Image
Capital Market
Last Updated : Oct 02 2021 | 11:50 AM IST

CRISIL Ratings has reaffirmed its 'CRISIL A+/Stable/CRISIL A1' ratings on the total bank facilities worth Rs 100 crore of Advanced Enzyme Technologies (Advanced Enzyme).

CRISIL Ratings said that the ratings continue to reflect strong operating efficiency of the company, driven by capabilities across the value chain, healthy relationships with customers, extensive experience of the promoters and a strong financial risk profile.

These strengths are partially offset by large working capital requirement and susceptibility to changes in food and drug safety regulations.

CRISIL said that the 'stable' outlook reflects the view that Advanced Enzyme should continue to benefit from its robust market position and healthy operating efficiency, while the financial risk profile should remain strong on account of adequate cash accrual and moderate capex.

Separately, Advanced Enzyme Technologies informed about the completion of the acquisition of additional stake of 15% in its subsidiary JC Biotech (JCB) by way of purchase of 31,06,680 equity shares from few selling shareholders of JCB, for a consideration of Rs 21.12 crore, i.e. Rs 68 per equity share. Accordingly, the shareholding of Advanced Enzyme in JCB has increased from 70% to 85%.

JCB is engaged in the business of manufacturing and sales of bio pharmaceuticals through the process of aerobic fermentation. It had reported turnover of Rs 50.4 crore, and PAT of Rs 7.8 crore for FY2020-21.

Advanced Enzyme is one of the largest enzyme companies in India, with competencies across the value chain: R&D, manufacturing and marketing/distribution of enzymes. The company operates two primary business segments: healthcare and nutrition and bioprocessing. It has multiple subsidiaries operating in similar businesses.

Advanced Enzyme's consolidated net profit rose 11.07% to Rs 38.04 crore on 23.99% increase in net sales to Rs 137.01 crore in Q1 FY22 over Q1 FY21.

The scrip rose 1.84% to end at Rs 377.25 on Wednesday. The domestic equity market is shut today, 19 August 2021, on account of Muharram.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 19 2021 | 5:00 PM IST

Next Story